title: Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
abstract: BACKGROUND
  Adolescent obesity is a major public health problem. Treatment options in addition to behavioral therapy could include pharmacotherapy with sibutramine.
  
  
  OBJECTIVE
  Concerns regarding increases in blood pressure and heart rate after sibutramine treatment in some adult patients precipitated the present analysis, which evaluated the cardiovascular safety of sibutramine plus a behavioral therapy program in obese adolescents.
  
  
  METHODS
  With this 12-month, randomized, double-blind, placebo-controlled trial in 33 US clinics we studied 498 adolescents aged 12 to 16 years with multiethnic backgrounds and BMIs of 28.1 to 46.3 kg/m2.
  
  
  RESULTS
  The subjects were randomly assigned to behavioral therapy plus 10 mg of sibutramine or behavioral therapy plus placebo daily. At the end point, there was a mean treatment group difference in BMI of 2.6 kg/m2 in favor of sibutramine. Small mean decreases in blood pressure and pulse rate were seen in both sibutramine and placebo groups at the end point (systolic blood pressure: -2.1 vs -2.1 mmHg; diastolic blood pressure: -0.1 vs -1.1 mmHg; pulse rate: -0.2 vs -1.8 bpm). In both treatment groups, these reductions in vital signs were greater at the end point when BMI reduction was > or = 5% compared with < 5%.
  
  
  CONCLUSIONS
  Sibutramine may have some direct cardiovascular effects on obese adolescents. These cardiovascular effects may be balanced by a reduction in BMI, which, in adolescents, seems to be greater than that observed in adults.
authors.affiliation: Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. daniels.stephen@tchden.org
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Daniels
authors.forename: Barbara
authors.initials: B
authors.lastname: Long
authors.forename: Scott
authors.initials: S
authors.lastname: Crow
authors.forename: Dennis
authors.initials: D
authors.lastname: Styne
authors.forename: Melinda
authors.initials: M
authors.lastname: Sothern
authors.forename: Ileana
authors.initials: I
authors.lastname: Vargas-Rodriguez
authors.forename: Lisa
authors.initials: L
authors.lastname: Harris
authors.forename: Julia
authors.initials: J
authors.lastname: Walch
authors.forename: Olga
authors.initials: O
authors.lastname: Jasinsky
authors.forename: Kristine
authors.initials: K
authors.lastname: Cwik
authors.forename: Ann
authors.initials: A
authors.lastname: Hewkin
authors.forename: Vicky
authors.initials: V
authors.lastname: Blakesley
mesh_terms: D000293:Adolescent; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D002648:Child; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy*
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine